Medication-Related Osteonecrosis of the Jaw Osteonecrosis Bisphosphonates Denosumab Bisphosphonate-Associated Osteonecrosis of the Jaw Cell Death
Conditions
Interventions
Healthy patients without a history of receiving antiresorptive medication who have mandibular tori, palatal tori, or alveolar bone exostosis. These patients have a plan for torectomy or alveoloplasy s
Basic Science,Basic Science
Healthy patients,MRONJ patients
Sponsors
Faculty of Dentistry, Chiang Mai University
Eligibility
Sex/Gender
All
Age
25 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients are 25 years old or over. 2. Patients with a history of receiving bisphosphonate or denosumab who have been diagnosed with MRONJ. (for MRONJ patients) 3. Patients with bony sequestrum who are undergoing sequestrectomy surgical procedures. (for MRONJ patients) 4. Patients with mandibular tori, palatal tori, or alveolar bone exsostosis who are undergoing torectomy or alveoloplasty surgical procedures. (for Healthy patients)
Exclusion criteria
Exclusion criteria: 1. Patients with a history of health conditions or receiving other medication that affects the bone remodeling process such as uncontrol Diabetes Mellitus patients, or steroid-receiving patients. 2. Patients with a history of metastatic cancer in the oral and maxillofacial region. 3. Patients with a history of head and neck radiation therapy. 4. Heavy smoking patients. 5. Alcoholic patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dominant pathway of cell death at 6 months after surgery. qRT-PCR and Western blotting | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical characteristics at 6 months after surgery. Examination,Radiographical characteristics at 6 months after surgery. Radiographical examination (orthopantomography) | — |
Countries
Thailand
Contacts
Public ContactBhumrapee Srivichit
Chiang Mai University
Outcome results
None listed